CHANGCHUN, China, Nov. 10 /Xinhua-PRNewswire/ --Global Pharmatech, Inc.
(OTC Bulletin Board: GBLP) a company that develops, manufactures and markets
proprietary botanical drugs and dietary supplements, today announced that the
State Intellectual Property Office of the P. R. China has recently granted a
new innovation patent to one of its botanical drug candidates, XNYDT
(Xianniuyaoditong) granule (patent number: ZL200310109939.3) to Natural
Pharmatech (Jilin), a wholly owned subsidiary of Global Pharmatech, Inc.
(Logo: http://www.prnasia.com/sa/200611101343.JPG )
The drug was developed according to previous clinical experience of
traditional Chinese medicine. XNYDT granule is potentially indicated for the
treatment of lumbosacral pain. Investigational New Drug (IND) application of
XNYDT was approved by the SFDA, Chinese regulatory authority on June 1, 2005.
Global Pharmatech is ready to start clinical development of this product.
XNYDT is a botanical drug product, which is formulated using modern
pharmaceutical technologies. Estimated cost of producing XNYDT is relatively
lower than other traditional herbal products for the treatment of lumbosacral
pain. Based on the data obtained from preliminary tests and previous clinical
experiences of traditional Chinese medicine, this product is expected to have
reasonable safety profile and to be more efficacies in comparison to other
botanical products for the same indication on Chinese market.
Lumbosacral pain is one of common chronic clinical problems in China. It
could be induced by various causes. Dr. Xiaobo Sun, President and CEO of
Global Pharmatech indicated: “We are very glad to have a new drug candidate
on our pipeline. This product will bring our company into a new therapeutic
area. We believe that we will complete our clinical program of XNYDT for the
SFDA market approval within the next three to four years.”
About Global Pharmatech
Global Pharmatech, through its subsidiaries, develops, manufactures and
markets proprietary drugs that are based on Traditional Chinese Medicine
using modern facilities and advanced R&D technologies. The company offers a
full range of start-to-finish biotech services, from research and testing to
manufacture and sale of liquid and solid dose products. The Company employs
unique proprietary extraction methods and also licenses patents and
technologies for botanical/biological drug products. Global Pharmatech’s
operations are currently based in the People’s Republic of China with sales
distribution centers in China, Malaysia, Singapore and Indonesia. For more
information, please visit Global Pharmatech.com
Safe Harbor Statement under the Private Securities Litigation Reform Act
of 1995
This news release contains forward-looking statements within the meaning
of the “safe harbour” provisions of the Private Securities Litigation
Reform Act of 1995. These statements are based upon our current expectations
and speak only as of the date hereof. Our actual results may differ
materially and adversely from those expressed in any forward-looking
statements as a result of various factors and uncertainties, including our
ability to successfully develop and commercialize products, competitive
products in our key markets, changes in consumer demand for our products,
legislative, regulatory and competitive developments and general economic
conditions. Our SEC filings discuss some of the important risk factors that
may affect our business, results of operations and financial condition. We
undertake no obligation to revise or update publicly any forward-looking
statements for any reason.